<DOC>
	<DOCNO>NCT00250250</DOCNO>
	<brief_summary>Children growth failure due inadequate secretion growth hormone growth retardation due Turner 's syndrome individually dose treated 12 week</brief_summary>
	<brief_title>An Open-Label , Multi-centre , Phase III Study Local Tolerability ZOMACTON 10MG</brief_title>
	<detailed_description>Ferring Pharmaceuticals A/S develop new ZOMACTON 10 mg formulation . The formulation provide high concentration thereby small volume administer . ZomaJet Vision X needle-free injection system . It send thin jet ZOMACTON skin subcutaneous tissue without use needle . The mode administration refer `` transjection '' . By use ZomaJet Vision X , transjection reconstitution ZOMACTON 10 mg do without use needle . The rationale study describe local tolerability new ZOMACTON 10 mg administer ZomaJet Vision X .</detailed_description>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<criteria>Subjects age 3 17 year ( inclusive ) growth failure due inadequate secretion growth hormone growth retardation due Turner 's syndrome . Subjects minimum 6 month prior study enrolment receive growth hormone therapy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>